Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 21;42(3):81.
doi: 10.1007/s12032-025-02629-0.

From conventional to cutting edge: an exploration of osteosarcoma treatments

Garen S Sellers  1 , McKade A Poirier  1 , Trenton G Mayberry  2 , Braydon C Cowan  2 , Mark R Wakefield  2 , Yujiang Fang  3   4
Affiliations
Review

From conventional to cutting edge: an exploration of osteosarcoma treatments

Garen S Sellers et al. Med Oncol. .

Abstract

Osteosarcoma is a highly aggressive cancer in children and young adults that has a remarkably high mortality rate upon metastasis. Current standard treatments have remained largely unchanged for nearly five decades, focusing on a combination of chemotherapy with high-dose methotrexate, doxorubicin, and cisplatin, complemented by aggressive surgical resections. Despite this lack of change, recent advancements in medical research have spurred hope for more effective and less invasive approaches to managing osteosarcoma. In this review, we provide an overview of existing therapeutic modalities, including chemotherapy regimens tailored to tumor stage and patient response, radiation therapies aimed at local tumor control, and advanced surgical techniques such as limb-sparing procedures. Additionally, we explore two promising future treatments that are currently under investigation for osteosarcoma cases: targeted therapies utilizing nanomaterials like graphene oxide and innovative oncolytic viruses. This review highlights potential breakthroughs in treatment options while identifying areas that warrant further investigation in the management of osteosarcoma. Considering the limited advancements in treatment over the past decades, identifying and highlighting novel and effective therapies is vital for improving patient outcomes and survival rates.

Keywords: Cancer immunotherapy; Oncolytic viruses; Osteosarcoma; Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

References

    1. Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4:25–43. https://doi.org/10.1007/s40744-016-0050-2 . - DOI - PubMed
    1. Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066–76. https://doi.org/10.1056/NEJMra2103423 . - DOI - PubMed
    1. Rathore R, Van Tine BA. Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies. J Clin Med. 2021;10(6):1182. https://doi.org/10.3390/jcm10061182 . - DOI - PubMed - PMC
    1. Pilavaki P, Gahanbani Ardakani A, Gikas P, Constantinidou A. Osteosarcoma: current concepts and evolutions in management principles. J Clin Med. 2023;12(8):2785. https://doi.org/10.3390/jcm12082785 . - DOI - PubMed - PMC
    1. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011: 959248. https://doi.org/10.1155/2011/959248 . - DOI - PubMed - PMC

LinkOut - more resources